



STOP: TEST FOR ALL 10 BIOMARKERS

Don't move forward with first-line therapy without a clear view ahead

NSCLC



Biomarker	Guideline-recommended	Emerging target*	FDA-approved matched therapy	Associated therapy (overall response rate)
<i>EGFR</i> exon 19 del, L858R and other alterations	●		●	TAGRISSO®, TARCEVA®, GILOTRIF®, IRESSA®, VIZIMPRO® (60-80%) ¹⁻⁹
<i>ALK</i> fusions	●		●	ALECENSA®, ALUNBRIG®, ZYKADIA®, XALKORI®, LORBRENA® (40-80%) ¹⁰⁻¹⁶
<i>ROS1</i> fusions	●		●	XALKORI®, ROZLYTREK™, (72-78%) ¹⁷⁻¹⁸
<i>BRAF</i> V600E	●		●	TAFINLAR® + MEKINIST®, (65%) ¹⁹
<i>NTRK</i> fusions	●		●	VITRAKVI®, ROZLYTREK™, (57-75%)* ^{18, 20}
<i>MET</i> exon 14 skipping	●		●	TABRECTA™ (41-68%) ²¹
<i>RET</i> fusions	●		●	RETEVMO™ (64-85%) ²²
<i>ERBB2</i> exon 20 insertions and other alterations	●	●		KADCYLA®^ (45%) ²³ , HERCEPTIN®^ combinations (50%) ²⁴
<i>KRAS</i> mutations	●			<i>KRAS</i> mutations usually do not overlap with other driver mutations and can indicate that no additional genomic testing is necessary ²⁵⁻²⁷
PD-L1	●		●	KEYTRUDA® (27-39%) ²⁸

STOP

Test every newly diagnosed advanced NSCLC patient for all 10 NCCN guideline biomarkers

WAIT

Wait for complete results to determine the most effective therapy

TREAT

Confidently choose the best possible first-line treatment – targeted therapy or immunotherapy +/- chemotherapy

* Drugs associated with emerging targets are only available as off-label

^ US FDA-approved in another indication

* Response rate is based on studies involving multiple cancer types
For references 1-28, visit [ClearYourView.org](https://clearyourview.org)

Supported by:



ClearYourView.org